(BIO) Bio-Rad Laboratories - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0905722072
Stock: Instruments, Reagents, Test Systems, Consumables
Total Rating 27
Risk 92
Buy Signal -1.70
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 34.8% |
| Relative Tail Risk | -9.60% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.27 |
| Alpha | -33.66 |
| Character TTM | |
|---|---|
| Beta | 1.050 |
| Beta Downside | 0.738 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.95% |
| CAGR/Max DD | -0.26 |
Description: BIO Bio-Rad Laboratories January 08, 2026
Bio-Rad Laboratories (NYSE:BIO) is a global supplier of life-science research and clinical-diagnostic products, operating through two segments: Life Science and Clinical Diagnostics. The firm designs, manufactures, and markets instruments, reagents, consumables, and software that enable the separation, purification, characterization, and quantitation of biological materials for applications ranging from biopharma manufacturing and quality control to food safety and academic research.
Key metrics that analysts watch include FY2023 revenue of roughly $3.2 billion, an operating margin near 22 %, and R&D spending at about 10 % of sales-levels that reflect the capital-intensive nature of the sector. Growth is driven by sustained biotech R&D investment (global spend exceeding $200 billion) and continued demand for clinical-diagnostic testing, especially in infectious-disease and personalized-medicine markets. The company’s mixed-channel distribution model (direct sales plus distributors, agents, and brokers) helps it capture market share across diverse geographies.
For a deeper quantitative assessment of BIO’s valuation and risk profile, you might explore the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -675.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.36 > 1.0 |
| NWC/Revenue: 90.70% < 20% (prev 99.13%; Δ -8.42% < -1%) |
| CFO/TA 0.05 > 3% & CFO 491.5m > Net Income -675.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (26.9m) vs 12m ago -3.79% < -2% |
| Gross Margin: 52.26% > 18% (prev 0.54%; Δ 5172 % > 0.5%) |
| Asset Turnover: 25.20% > 50% (prev 24.33%; Δ 0.86% > 0%) |
| Interest Coverage Ratio: -16.17 > 6 (EBITDA TTM -621.3m / Interest Expense TTM 49.1m) |
Altman Z'' 6.14
| A: 0.24 (Total Current Assets 2.84b - Total Current Liabilities 522.3m) / Total Assets 9.70b |
| B: 0.77 (Retained Earnings 7.46b / Total Assets 9.70b) |
| C: -0.08 (EBIT TTM -793.5m / Avg Total Assets 10.15b) |
| D: 2.46 (Book Value of Equity 7.29b / Total Liabilities 2.96b) |
| Altman-Z'' Score: 6.14 = AAA |
Beneish M -3.10
| DSRI: 1.04 (Receivables 474.2m/461.9m, Revenue 2.56b/2.58b) |
| GMI: 1.04 (GM 52.26% / 54.41%) |
| AQI: 0.98 (AQ_t 0.63 / AQ_t-1 0.64) |
| SGI: 0.99 (Revenue 2.56b / 2.58b) |
| TATA: -0.12 (NI -675.9m - CFO 491.5m) / TA 9.70b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of BIO shares?
As of February 05, 2026, the stock is trading at USD 298.98 with a total of 367,224 shares traded.
Over the past week, the price has changed by +0.43%, over one month by -7.25%, over three months by -4.00% and over the past year by -15.33%.
Over the past week, the price has changed by +0.43%, over one month by -7.25%, over three months by -4.00% and over the past year by -15.33%.
Is BIO a buy, sell or hold?
Bio-Rad Laboratories has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy BIO.
- StrongBuy: 2
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 348 | 16.4% |
| Analysts Target Price | 348 | 16.4% |
| ValueRay Target Price | 261.9 | -12.4% |
BIO Fundamental Data Overview February 03, 2026
P/E Forward = 30.8642
P/S = 3.0978
P/B = 1.1809
P/EG = 1.1905
Revenue TTM = 2.56b USD
EBIT TTM = -793.5m USD
EBITDA TTM = -621.3m USD
Long Term Debt = 1.20b USD (from longTermDebt, last quarter)
Short Term Debt = 38.1m USD (from shortTermDebt, last quarter)
Debt = 1.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 997.5m USD (from netDebt column, last quarter)
Enterprise Value = 8.92b USD (7.92b + Debt 1.40b - CCE 395.8m)
Interest Coverage Ratio = -16.17 (Ebit TTM -793.5m / Interest Expense TTM 49.1m)
EV/FCF = 26.49x (Enterprise Value 8.92b / FCF TTM 336.7m)
FCF Yield = 3.77% (FCF TTM 336.7m / Enterprise Value 8.92b)
FCF Margin = 13.17% (FCF TTM 336.7m / Revenue TTM 2.56b)
Net Margin = -26.43% (Net Income TTM -675.9m / Revenue TTM 2.56b)
Gross Margin = 52.26% ((Revenue TTM 2.56b - Cost of Revenue TTM 1.22b) / Revenue TTM)
Gross Margin QoQ = 52.59% (prev 52.99%)
Tobins Q-Ratio = 0.92 (Enterprise Value 8.92b / Total Assets 9.70b)
Interest Expense / Debt = 0.88% (Interest Expense 12.3m / Debt 1.40b)
Taxrate = 21.0% (US default 21%)
NOPAT = -626.9m (EBIT -793.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.44 (Total Current Assets 2.84b / Total Current Liabilities 522.3m)
Debt / Equity = 0.21 (Debt 1.40b / totalStockholderEquity, last quarter 6.74b)
Debt / EBITDA = -1.61 (negative EBITDA) (Net Debt 997.5m / EBITDA -621.3m)
Debt / FCF = 2.96 (Net Debt 997.5m / FCF TTM 336.7m)
Total Stockholder Equity = 6.78b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.66% (Net Income -675.9m / Total Assets 9.70b)
RoE = -9.97% (Net Income TTM -675.9m / Total Stockholder Equity 6.78b)
RoCE = -9.94% (EBIT -793.5m / Capital Employed (Equity 6.78b + L.T.Debt 1.20b))
RoIC = -7.85% (negative operating profit) (NOPAT -626.9m / Invested Capital 7.98b)
WACC = 8.42% (E(7.92b)/V(9.32b) * Re(9.78%) + D(1.40b)/V(9.32b) * Rd(0.88%) * (1-Tc(0.21)))
Discount Rate = 9.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.34%
[DCF Debug] Terminal Value 79.91% ; FCFF base≈291.6m ; Y1≈359.6m ; Y5≈612.5m
Fair Price DCF = 389.9 (EV 9.54b - Net Debt 997.5m = Equity 8.54b / Shares 21.9m; r=8.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -63.11 | EPS CAGR: -54.35% | SUE: -4.0 | # QB: 0
Revenue Correlation: -70.64 | Revenue CAGR: -3.03% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.51 | Chg30d=-0.030 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=10.15 | Chg30d=-0.184 | Revisions Net=-2 | Growth EPS=+2.0% | Growth Revenue=+2.2%
P/S = 3.0978
P/B = 1.1809
P/EG = 1.1905
Revenue TTM = 2.56b USD
EBIT TTM = -793.5m USD
EBITDA TTM = -621.3m USD
Long Term Debt = 1.20b USD (from longTermDebt, last quarter)
Short Term Debt = 38.1m USD (from shortTermDebt, last quarter)
Debt = 1.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 997.5m USD (from netDebt column, last quarter)
Enterprise Value = 8.92b USD (7.92b + Debt 1.40b - CCE 395.8m)
Interest Coverage Ratio = -16.17 (Ebit TTM -793.5m / Interest Expense TTM 49.1m)
EV/FCF = 26.49x (Enterprise Value 8.92b / FCF TTM 336.7m)
FCF Yield = 3.77% (FCF TTM 336.7m / Enterprise Value 8.92b)
FCF Margin = 13.17% (FCF TTM 336.7m / Revenue TTM 2.56b)
Net Margin = -26.43% (Net Income TTM -675.9m / Revenue TTM 2.56b)
Gross Margin = 52.26% ((Revenue TTM 2.56b - Cost of Revenue TTM 1.22b) / Revenue TTM)
Gross Margin QoQ = 52.59% (prev 52.99%)
Tobins Q-Ratio = 0.92 (Enterprise Value 8.92b / Total Assets 9.70b)
Interest Expense / Debt = 0.88% (Interest Expense 12.3m / Debt 1.40b)
Taxrate = 21.0% (US default 21%)
NOPAT = -626.9m (EBIT -793.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.44 (Total Current Assets 2.84b / Total Current Liabilities 522.3m)
Debt / Equity = 0.21 (Debt 1.40b / totalStockholderEquity, last quarter 6.74b)
Debt / EBITDA = -1.61 (negative EBITDA) (Net Debt 997.5m / EBITDA -621.3m)
Debt / FCF = 2.96 (Net Debt 997.5m / FCF TTM 336.7m)
Total Stockholder Equity = 6.78b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.66% (Net Income -675.9m / Total Assets 9.70b)
RoE = -9.97% (Net Income TTM -675.9m / Total Stockholder Equity 6.78b)
RoCE = -9.94% (EBIT -793.5m / Capital Employed (Equity 6.78b + L.T.Debt 1.20b))
RoIC = -7.85% (negative operating profit) (NOPAT -626.9m / Invested Capital 7.98b)
WACC = 8.42% (E(7.92b)/V(9.32b) * Re(9.78%) + D(1.40b)/V(9.32b) * Rd(0.88%) * (1-Tc(0.21)))
Discount Rate = 9.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.34%
[DCF Debug] Terminal Value 79.91% ; FCFF base≈291.6m ; Y1≈359.6m ; Y5≈612.5m
Fair Price DCF = 389.9 (EV 9.54b - Net Debt 997.5m = Equity 8.54b / Shares 21.9m; r=8.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -63.11 | EPS CAGR: -54.35% | SUE: -4.0 | # QB: 0
Revenue Correlation: -70.64 | Revenue CAGR: -3.03% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.51 | Chg30d=-0.030 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=10.15 | Chg30d=-0.184 | Revisions Net=-2 | Growth EPS=+2.0% | Growth Revenue=+2.2%